Listed by the USPTO as ABBOTT, KODYE LEE
Tech Center 1600 • Art Units: 1632 1634
This examiner grants 54% of resolved cases
ABBOTT, KODYE LEE is assigned to Tech Center 1600 and Art Unit 1632, with 33 resolved cases. The allowance rate is 54.5%, and the median time to allowance is 1298 days. The interview lift is 71.4%, the largest recorded interview-associated change in this profile, making interview planning an especially relevant consideration.
University of Massachusetts, Ucl Business Ltd., and Wisconsin Alumni Research Foundation are the leading companies or institutions represented. The listed firms are BANNER & WITCOFF, LTD., Bridgeway IP Law Group, PLLC, and Clark+Elbing LLP. The combination of extended median timing and substantial interview lift suggests that applicants may benefit from focused interviews that address the examiner's outstanding issues directly.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19637632 | CIRCULAR RNA VECTORS COMPRISING MODIFIED NUCLEOTIDES | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18625271 | HIGH THROUGHPUT LOCALIZED PASSIVE DIFFUSION DEVICE FOR PATTERNING ORGANOIDS | Non-Final OA | University of Massachusetts |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | Non-Final OA | UCL BUSINESS LTD |
| 18255444 | RETROVIRAL VECTORS | Final Rejection | UCL Business LTD |
| 18982272 | Method for the Induction of Arterial-Type of Hemogenic Endothelium from hPSCS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17634720 | IMMUNORESPONSIVE CELLS ARMOURED WITH SPATIOTEMPORALLY RESTRICTED ACTIVITY OF CYTOKINES OF THE IL-1 SUPERFAMILY | Final Rejection | King's College London |
| 17921174 | ISOLATION AND FUNCTIONAL ANALYSIS OF EPITHELIAL PROGENITOR CELLS FROM THE HUMAN LUNG | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | Final Rejection | BIOVENTURES, LLC |
| 17773467 | METHOD FOR PRODUCING T CELLS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17605639 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION | Final Rejection | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17703094 | Producer Viruses for Generation of Retroviruses In Situ | Non-Final OA | KaliVir Immunotherapeutics, Inc. |
| 17759647 | PROCESS AND SYSTEM FOR ACELLULAR THERAPY | Final Rejection | Orgenesis Inc. |
| 18268597 | Medium for the in vitro transportation and storage of cells | Final Rejection | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | Non-Final OA | Angiocrine Bioscience, Inc. |
| 18285057 | METHOD FOR CELL TRANSDUCTION AND MICROFLUIDIC CHIP FOR CELL TRANSDUCTION | Non-Final OA | CTCELLS, INC. |
| 17631048 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33 | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 18592249 | APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS | Non-Final OA | ALLIFE MEDICINE (BEIJING) LIMITED |
| 17756814 | IMPROVED PROCESS FOR CULTURING TUMOR-INFILTRATING LYMPHOCYTES FOR THERAPEUTIC USE | Final Rejection | Cbio A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.5% of resolved applications examined by Kodye Lee Abbott were allowed (33 resolved cases), compared with 38.1% across Art Unit 1632 over the last five years.
This examiner's interview lift is +71.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kodye Lee Abbott took 1,298 days on average from filing to allowance.
Kodye Lee Abbott examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
